2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Transplantation, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

1858 Comparative effectiveness of modern induction regimens and the impact of autologous stem cell transplantation (ASCT) in primary cns lymphoma (PCNSL): A large multicenter real-world analysis

Madiha Iqbal, MBBS, MD, Tristan L'Esperance, MD2, Cassandra Duarte, MD3, Mohamed Rajab4, Steven Hwang, MD, BS5, Ayo Samuel Falade, MD, MBA6, Zhuo Li7, Launia White8, Kehua Zhou9, Allison Marie Bock, MD10, Jessica Zhu, MD11, Elif Yilmaz, MD12, Raamis Khwaja13, Eric Mou, MD14, Aubriannah Larson, MD15, Jose Sandoval-Sus I, MD16, Abat Khan, MD17, Ariel Perez, MD18, Yuliya Linhares19, Tiba Al Sagheer, Pharm.D., BCOP, BCACP20, Ajay Major, MD, MBA21, Perla R. Colunga-Pedraza I, MD22, Hector Alejandro Vaquera-Alfaro, MD23, Mengyang Di, MD, PhD24, Brenda Sofia Castillo, MD25, Mazie Tsang, MD, MAS, MS26, Yun Kyoung Tiger, MD, PhD27, Muhamad Alhaj Moustafa, MD, MS28, Thomas M. Habermann, MD29, Julio C Chavez, MD, MS30, Han W Tun, MD31, Patrick Johnston, MD, PhD32, Arushi Khurana, MBBS33
1 Mayo Clinic, Jacksonville, Florida, United States
2 University of Wisconsin, Madison, Florida, United States
3 University of Colorado, Aurora, Colorado, United States
4 HCA Florida Brandon Hospital, Brandon, Florida, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 University of Colorado, Aurora, Colorado, United States
10 University of Utah, Salt Lake City, Utah, United States
11 University of Utah, Salt Lake City, Utah, United States
12 UT Southwestern, Dallas, Texas, United States
13 UT Southwestern, Dallas, Texas, United States
14 University of Iowa, Iowa, Iowa, United States
15 University of Iowa, Iowa, Iowa, United States
16 Moffit Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, United States
17 Moffit Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, United States
18 Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
19 Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
20 Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
21 University of Colorado, Aurora, Colorado, United States
22 Dr. José Eleuterio Gonzalez University Hospital, Monterrey, United States
23 Dr. José Eleuterio Gonzalez University Hospital, Monterrey, United States
24 Fred Hutchinson Cancer Center, Seattle, United States
25 Fred Hutchinson Cancer Center, Seattle, United States
26 Mayo Clinic, Pheonix, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Mayo Clinic, Jacksonville, Florida, United States
29 Mayo Clinic, Rochester, Minnesota, United States
30 Mayo Clinic, Jacksonville, Florida, United States
31 Mayo Clinic, Jacksonville, Florida, United States
32 Mayo Clinic, Rochester, Minnesota, United States
33 Mayo Clinic, Rochester, Minnesota, United States

Background: Treatment of PCNSL has evolved from whole brain radiation therapy to high dose (HD)-Methotrexate (MTX) based induction regimens, improving outcomes while reducing neurotoxicity. Multiple HD-MTX based combinations are currently used, but evidence is derived from phase II studies with limited direct comparisons. Given differences across regimens, we conducted a multi-center study to compare effectiveness and safety of contemporary induction strategies for PCNSL.

Methods: A total of 501 patients with newly diagnosed PCNSL received MTX, rituximab, temozolomide (MRT) (n=243), MTX, rituximab (MR) (n=64), MTX, thiotepa, cytarabine (MATRIX) (n=24), rituximab, MTX, procarbazine, vincristine (R-MPV) (n=144), or “Other” regimens (n=26). "Other" was defined as non-protocol HD-MTX–based regimens (including HD-MTX monotherapy). Overall survival (OS) and progression free survival (PFS) were estimated from treatment initiation using Kaplan Meier method and predictors were evaluated with Cox models. To minimize immortal-time bias, a 6 month landmark analysis was performed, including only patients alive and progression free (n=399).

Results: Median age of the cohort was 65 (range 18-85 years (yrs)) and differed by regimen (p<0.001), MATRIX patients were younger (median 55.5 yrs) and MR patients older (median 68.5 yrs). Race, ECOG, MYD88 status, EBV status, LDH, HIV status, immune status, IELSG score, vitreoretinal involvement and intraocular-only disease differed across regimens (p<0.05). MTX intensity (5.1 g/m2) were highest with MRT but lowest with MATRIX (3.5 g/m2) (p<0.001).

Interim ORR did not differ (p=0.52) but end of induction (EOI) ORR (p=0.015), and time to interim and EOI response (p<0.001) differed by regimen. EOI responses were highest with MRT (CR 67.9%, ORR 90.2%) and R-MPV (CR 66.9%, ORR 90.3%) followed by MATRIX (CR 60.9%, ORR 82.6%) and lowest with “Other” (ORR: 64.7%) regimens. The incidence of grade 3-4 hematologic toxicities, infections and non-hematological toxicities differed by regimen (p<0.05). MATRIX carried a high toxicity burden, including grade 4 hematological toxicity (95.5%), infections (82.6%) (p<0.001) and treatment delays (43.5%) (p=0.052). Overall, 205 patients (41.1%) proceeded to ASCT and 294 (58.9%) did not.

 With a median follow up of 33.4 months (range: 0.1-179), 5-year OS and PFS were 57.2% (95%CI 52.4-62.3) and 47.2% (95%CI 42.5-52.5), respectively, and varied significantly by induction regimen. MRT achieved the best outcomes (5-year OS 63.3%, PFS 53.8%), while “Other” regimens had the poorest survival (OS 31.9%, PFS 31.7%). ASCT was associated with markedly improved outcomes, with higher 5-year OS (73.8% vs. 46.1%) and PFS (61.3% vs. 37.3%) compared with no ASCT. On multivariable analysis adjusted for age, immune status, ECOG,  and induction regimen, “Other” regimens were independently associated with increased mortality versus MRT (HR 2.25, 95% CI 1.08–4.65, p=0.0295), whereas MR, MATRIX, and R-MPV showed no significant difference. ASCT remained a strong independent predictor of reduced mortality (HR 0.35, p<0.001). In the landmark analysis cohort, ASCT remained associated with superior OS (HR 0.54, 95% CI 0.38–0.77; p<0.001) and PFS (HR 0.60, 95% CI 0.41–0.86; p=0.006).

Among ASCT recipients (n=205; median age:61 yrs), induction regimen did not impact OS or PFS, whereas receiving only one line of therapy before ASCT was associated with improved PFS compared with 2 or more prior lines (71.4% vs. 28.4%, p<0.001). Among non-ASCT recipients (n=294; median age: 69 yrs), OS differed by induction regimen (p=0.044), with MRT showing the best 5-year OS (53.4%) and MATRIX and “Other” the worst (33.3% and 24.6%, respectively). Post-induction management also differed by regimen (p<0.001), MTX maintenance was used in 25.7% overall, including 38% of MRT and 50% of MR patients but 0% in others, who were managed with observation (25.7%) or alternative approaches (48.5%; (WBRT, BTK inhibitors, ImiDs,HiDAC). Neither MTX maintenance nor alternative approaches were associated with OS (p=0.45) or PFS (p=0.12).

Conclusion: Management of PCNSL varied notably across centers and patient populations. Long-term outcomes differed by induction strategy, with MRT achieving the most favorable outcomes and non-protocol regimens the worst. ASCT remained a key independent predictor of survival, underscoring the value of effective, low-toxicity induction approaches that enable successful transplantation.
Madiha Iqbal, MBBS, MD: No relevant conflicts of interest to declare.